Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer
Authors
Keywords
-
Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume -, Issue -, Pages -
Publisher
American Chemical Society (ACS)
Online
2021-07-29
DOI
10.1021/acs.jmedchem.1c00876
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems
- (2021) Xiaojuan Qu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
- (2020) George M. Burslem et al. CELL
- Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)
- (2020) Hao Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- In silico search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation
- (2020) Harun M. Patel et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma
- (2020) Rui Li et al. JOURNAL OF DRUG TARGETING
- Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders
- (2020) Meng Cheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design and synthesis of selective degraders of EGFRL858R/T790M mutant
- (2020) Xin Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC)
- (2020) Harun M. Patel et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
- (2020) Yuxin Mu et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy
- (2020) Yubo Wang et al. Journal of Thoracic Oncology
- Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations
- (2020) Jaebong Jang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide
- (2020) Kailun He et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation
- (2020) Zhicheng Su et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Proteolysis targeting chimeras (PROTACs) for epigenetics research
- (2020) Anja Vogelmann et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- (2020) Mingguang Zhang et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- Mechanisms of osimertinib resistance and emerging treatment options
- (2020) Sabine Schmid et al. LUNG CANCER
- Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment
- (2020) Juliana F. Vilachã et al. Crystals
- Discovery of potent small molecule PROTACs targeting mutant EGFR
- (2020) Hong-Yi Zhao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- (2020) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
- (2019) Masayuki Takeda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M‐Positive Non‐Small‐Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial
- (2019) Akira Nakao et al. ONCOLOGIST
- On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele specific manner dependent on the original EGFR activating mutation
- (2019) Benjamin P Brown et al. CLINICAL CANCER RESEARCH
- 114OPotential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study
- (2019) C Xu et al. ANNALS OF ONCOLOGY
- FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy
- (2019) Alvaro Quintanal-Villalonga et al. Journal of Thoracic Oncology
- Pre-clinical Modeling of Osimertinib for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
- (2019) Yusoo Lee et al. Journal of Thoracic Oncology
- Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S
- (2019) Qiannan Li et al. ACS Medicinal Chemistry Letters
- Single and dual targeting of mutant EGFR with an allosteric inhibitor
- (2019) Ciric To et al. Cancer Discovery
- Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer
- (2019) Yi‐Nan Liu et al. INTERNATIONAL JOURNAL OF CANCER
- Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)
- (2019) Jiayi Shen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro
- (2019) Toshio Fujino et al. Journal of Thoracic Oncology
- Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
- (2019) Santoni-Rugiu et al. Cancers
- EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib
- (2019) Lei Ma et al. Annals of Translational Medicine
- Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants
- (2019) Sean T. Toenjes et al. ACS Chemical Biology
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
- (2019) Alessandro Leonetti et al. BRITISH JOURNAL OF CANCER
- 2-Oxo-3,4-dihydropyrimido[4, 5-d] Pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant
- (2019) Xianglong Hu et al. CHINESE CHEMICAL LETTERS
- Exon-16-skipping HER2 as a novel mechanism of osimertinib-resistance in EGFR L858R/T790M-positive non-small-cell lung cancer
- (2019) Chia-Chi Hsu et al. Journal of Thoracic Oncology
- EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples
- (2019) Deepa Rangachari et al. Journal of Thoracic Oncology
- DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model
- (2019) Takeshi Jimbo et al. Oncotarget
- Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors
- (2019) Hao Lei et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Current Approaches in NSCLC Targeting K-RAS and EGFR
- (2019) Veronica Aran et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors
- (2019) Harald Engelhardt et al. JOURNAL OF MEDICINAL CHEMISTRY
- Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study
- (2019) Camille Mehlman et al. LUNG CANCER
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors
- (2019) Dries J. H. De Clercq et al. ACS Medicinal Chemistry Letters
- Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
- (2018) J Remon et al. ANNALS OF ONCOLOGY
- Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
- (2018) D Westover et al. ANNALS OF ONCOLOGY
- Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer
- (2018) C Ricordel et al. ANNALS OF ONCOLOGY
- Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045
- (2018) Peng Zhao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9 H -purine as new EGFR inhibitors
- (2018) Yuan-Yuan Hei et al. BIOORGANIC & MEDICINAL CHEMISTRY
- TargetingHER2Aberrations in Non–Small Cell Lung Cancer with Osimertinib
- (2018) Shengwu Liu et al. CLINICAL CANCER RESEARCH
- Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
- (2018) Zhe Yang et al. CLINICAL CANCER RESEARCH
- In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition
- (2018) Harun Patel et al. COMPUTATIONAL BIOLOGY AND CHEMISTRY
- Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials
- (2018) G.M. O’Kane et al. Current Oncology
- Discovery of 2,4,6-trisubstitued pyrido[3,4- d ]pyrimidine derivatives as new EGFR-TKIs
- (2018) Hao Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy
- (2018) Kenneth K.W. To et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib
- (2018) Jin Kang et al. Journal of Thoracic Oncology
- Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors
- (2018) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models
- (2018) Carminia Maria Della Corte et al. Journal of Thoracic Oncology
- EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib
- (2018) Qi Zhang et al. Journal of Thoracic Oncology
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- (2018) Marina Chiara Garassino et al. LANCET ONCOLOGY
- Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy
- (2018) R. Minari et al. LUNG CANCER
- EGFR-TKIs resistance via EGFR-independent signaling pathways
- (2018) Qian Liu et al. Molecular Cancer
- Osimertinib in EGFR Mutation–Positive Advanced NSCLC
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib as First-Line Treatment in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2018) Sanjay Popat NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
- (2018) Chia‐Yu Chu et al. ONCOLOGIST
- BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review
- (2018) Xuanzong Li et al. Targeted Oncology
- MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
- (2018) Kiichiro Ninomiya et al. Scientific Reports
- Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients
- (2018) Keke Nie et al. Biomed Research International
- Allosteric Inhibitor TREA-0236 Containing Non-hydrolysable Quinazoline-4-one for EGFR T790M/C797S Mutants Inhibition
- (2018) Seoyoung Lee et al. BULLETIN OF THE KOREAN CHEMICAL SOCIETY
- Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition
- (2018) Lei Deng et al. Journal of Thoracic Oncology
- Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report
- (2018) Jing Zhao et al. OncoTargets and Therapy
- A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group
- (2018) Tao Jiang et al. Journal of Thoracic Disease
- Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
- (2018) Geoffrey R. Oxnard et al. JAMA Oncology
- LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
- (2018) V A Papadimitrakopoulou et al. ANNALS OF ONCOLOGY
- LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
- (2018) S S Ramalingam et al. ANNALS OF ONCOLOGY
- Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC
- (2018) Ping Zhou et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Receptor Tyrosine Kinase-Targeted Cancer Therapy
- (2018) Toshimitsu Yamaoka et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
- (2018) Yangbing Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
- (2018) Benjamin J Solomon et al. LANCET ONCOLOGY
- Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells
- (2018) Kei Namba et al. MOLECULAR CANCER RESEARCH
- Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report
- (2018) Yan Zhang et al. OncoTargets and Therapy
- Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy
- (2018) Xiaoyun Lu et al. ACS Medicinal Chemistry Letters
- Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
- (2018) Jana Fassunke et al. Nature Communications
- Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
- (2018) Tatsuya Nagano et al. Cells
- Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
- (2018) Sha Zhao et al. LUNG CANCER
- A structure-guided optimization of pyrido[2,3- d ]pyrimidin-7-ones as selective inhibitors of EGFR L858R/T790M mutant with improved pharmacokinetic properties
- (2017) Lei Yu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance
- (2017) Harun Patel et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- MEK inhibitors under development for treatment of non-small-cell lung cancer
- (2017) Chul Kim et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
- (2017) Silvia La Monica et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping
- (2017) Michael Juchum et al. JOURNAL OF MEDICINAL CHEMISTRY
- Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer
- (2017) Lingfeng Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site
- (2017) Marcel Günther et al. JOURNAL OF MEDICINAL CHEMISTRY
- Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
- (2017) Imane Chaib et al. JNCI-Journal of the National Cancer Institute
- MA08.03 Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis
- (2017) Yi Long Wu et al. Journal of Thoracic Oncology
- Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance
- (2017) Zhen Wang et al. Journal of Thoracic Oncology
- P2.06-022 First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study
- (2017) Tony Mok et al. Journal of Thoracic Oncology
- Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR- Mutant Non–Small Cell Lung Cancer
- (2017) Emily R. York et al. Journal of Thoracic Oncology
- Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
- (2017) Chao-Chi Ho et al. Journal of Thoracic Oncology
- Combination Osimertinib and Gefitinib in C797S and T790M EGFR- Mutated Non–Small Cell Lung Cancer
- (2017) Surein Arulananda et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
- (2017) Alice T Shaw et al. LANCET ONCOLOGY
- Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
- (2017) A. Oztan et al. LUNG CANCER
- Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib
- (2017) Sai-Hong Ignatius Ou et al. LUNG CANCER
- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
- (2017) Collin M Blakely et al. NATURE GENETICS
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment
- (2017) Qian Liu et al. TUMOR BIOLOGY
- Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
- (2017) Ken Uchibori et al. Nature Communications
- Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
- (2017) Kirstine Jacobsen et al. Nature Communications
- EGFR G796D mutation mediates resistance to osimertinib
- (2017) Di Zheng et al. Oncotarget
- Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report
- (2017) Lin Li et al. Oncotarget
- Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer
- (2017) Jing Xu et al. Oncotarget
- Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
- (2017) Imane Chaib et al. JNCI-Journal of the National Cancer Institute
- Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation
- (2017) Meredith K Bollinger et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
- (2017) Tristan A. Barnes et al. Frontiers in Oncology
- Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR
- (2016) Julian Engel et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant
- (2016) Marcel Günther et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
- (2016) Puyu Shi et al. CANCER LETTERS
- Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
- (2016) S. Ortiz-Cuaran et al. CLINICAL CANCER RESEARCH
- The CXCL8-CXCR1/2 pathways in cancer
- (2016) Qian Liu et al. CYTOKINE & GROWTH FACTOR REVIEWS
- The safety and efficacy of osimertinib for the treatment ofEGFRT790M mutation positive non-small-cell lung cancer
- (2016) Xin Gao et al. Expert Review of Anticancer Therapy
- First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
- (2016) Alessandra Fabi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
- (2016) Shuhang Wang et al. Journal of Hematology & Oncology
- Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment
- (2016) Jun Soo Ham et al. Journal of Thoracic Oncology
- Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer
- (2016) Haa-Na Song et al. Journal of Thoracic Oncology
- L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC
- (2016) Melissa Bersanelli et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
- (2016) Scott Antonia et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment
- (2016) Puey Ling Chia et al. LUNG CANCER
- High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression
- (2016) Sai-Hong Ignatius Ou et al. LUNG CANCER
- Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
- (2016) Yong Jia et al. NATURE
- Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
- (2016) Michihiko Kuwano et al. PHARMACOLOGY & THERAPEUTICS
- Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors
- (2016) Ludmila Danilova et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
- (2016) Jacob J. Chabon et al. Nature Communications
- Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
- (2016) Ji Hyun Park et al. Oncotarget
- EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
- (2015) D. Planchard et al. ANNALS OF ONCOLOGY
- Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
- (2015) C. A. Eberlein et al. CANCER RESEARCH
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
- (2015) M. J. Niederst et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
- (2015) D. Ercan et al. CLINICAL CANCER RESEARCH
- Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas
- (2015) Juliana Eng et al. Journal of Thoracic Oncology
- Vortex Keratopathy Presumed Secondary to AZD9291
- (2015) Puey Ling Chia et al. Journal of Thoracic Oncology
- Mechanisms of Acquired Resistance to AZD9291
- (2015) Tae Min Kim et al. Journal of Thoracic Oncology
- Targeting HER2 in the treatment of non-small cell lung cancer
- (2015) Nataliya Mar et al. LUNG CANCER
- Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells
- (2015) Yongik Lee et al. MOLECULAR CARCINOGENESIS
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antagonists of PD-1 and PD-L1 in Cancer Treatment
- (2015) Evan J. Lipson et al. SEMINARS IN ONCOLOGY
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
- (2015) Matthew J. Niederst et al. Nature Communications
- Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor
- (2015) Helena A. Yu et al. JAMA Oncology
- Mechanisms of resistance to EGFR tyrosine kinase inhibitors
- (2015) Lihua Huang et al. Acta Pharmaceutica Sinica B
- Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma
- (2015) Kathleen M. Capaccione et al. Oncotarget
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Cetuximab Response of Lung Cancer-Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization
- (2013) J. Cho et al. CANCER RESEARCH
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer--Response
- (2013) M. Sznol et al. CLINICAL CANCER RESEARCH
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Signal transducers and activators of transcription 3 function in lung cancer
- (2013) Yue-Chuan Li et al. Journal of Cancer Research and Therapeutics
- Transformation to “high grade” neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma
- (2013) S. Popat et al. LUNG CANCER
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
- (2013) A. O. Walter et al. Cancer Discovery
- RAS signaling pathways, mutations and their role in colorectal cancer
- (2013) Kypros Zenonos World Journal of Gastrointestinal Oncology
- Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations
- (2012) Jiao Yang et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Frozen Analogue Approach to Aminopyridinylimidazoles Leading to Novel and Promising p38 MAP Kinase Inhibitors
- (2012) Roland Selig et al. JOURNAL OF MEDICINAL CHEMISTRY
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer
- (2011) Vienna Ludovini et al. Journal of Thoracic Oncology
- JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer
- (2011) Mei Zhao et al. LUNG CANCER
- Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling
- (2011) J. E. Chaft et al. MOLECULAR CANCER THERAPEUTICS
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- TGF- IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
- (2010) Z. Yao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients
- (2009) F. Cappuzzo et al. ANNALS OF ONCOLOGY
- Signal Transducer and Activator of Transcription-3, Inflammation, and Cancer
- (2009) Bharat B. Aggarwal et al. Annals of the New York Academy of Sciences
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
- (2009) M. L. Sos et al. CANCER RESEARCH
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More